Nasdaq:LENZ

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the…

4 hours ago